- $4.21bn
- $3.73bn
- $471.80m
- 83
- 15
- 60
- 52
2020 January 31st | 2021 January 31st | 2022 January 31st | 2023 January 31st | 2024 January 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 96.4 | 150 | 238 | 355 | 472 |
Cost of Revenue | |||||
Gross Profit | 60.7 | 95.7 | 160 | 240 | 324 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 130 | 182 | 316 | 504 | 616 |
Operating Profit | -33.5 | -32.2 | -78.2 | -148 | -145 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -31.4 | -31.4 | -78.3 | -140 | -128 |
Provision for Income Taxes | |||||
Net Income After Taxes | -31.8 | -32 | -78.2 | -141 | -130 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -31.8 | -31.8 | -76.7 | -139 | -129 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -31.8 | -31.8 | -76.7 | -139 | -129 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.352 | -0.352 | -0.825 | -1.47 | -1.31 |
Dividends per Share |